当前位置: X-MOL 学术ACS Med. Chem. Lett. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Discovery of VU6015929: A Selective Discoidin Domain Receptor 1/2 (DDR1/2) Inhibitor to Explore the Role of DDR1 in Antifibrotic Therapy.
ACS Medicinal Chemistry Letters ( IF 4.2 ) Pub Date : 2019-11-25 , DOI: 10.1021/acsmedchemlett.9b00382
Daniel E Jeffries 1 , Corina M Borza 2 , Anna L Blobaum 3, 4 , Ambra Pozzi 2, 5 , Craig W Lindsley 1, 3, 4
Affiliation  

Herein, we report the discovery of a potent and selective dual DDR1/2 inhibitor, 7e (VU6015929), displaying low cytotoxicity, good kinome selectivity, and possessing an acceptable in vitro DMPK profile with good rodent in vivo pharmacokinetics. VU6015929 potently blocks collagen-induced DDR1 activation and collagen-IV production, suggesting DDR1 inhibition as an exciting target for antifibrotic therapy.

中文翻译:

VU6015929的发现:一种选择性Discoidin域受体1/2(DDR1 / 2)抑制剂,可探索DDR1在抗纤维化治疗中的作用。

在这里,我们报告发现了一种有效的,选择性的双重DDR1 / 2抑制剂7e(VU6015929),它显示出低细胞毒性,良好的运动组选择性,并具有可接受的体外DMPK谱以及良好的啮齿类动物体内药代动力学。VU6015929有效阻止胶原蛋白诱导的DDR1激活和胶原蛋白IV的产生,表明DDR1抑制是抗纤维化治疗的令人兴奋的目标。
更新日期:2019-12-06
down
wechat
bug